These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2323828)

  • 1. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103.
    Ketley JM; Kaper JB; Herrington DA; Losonsky G; Levine MM
    Infect Immun; 1990 May; 58(5):1481-4. PubMed ID: 2323828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.
    Cryz SJ; Kaper J; Tacket C; Nataro J; Levine MM
    Dev Biol Stand; 1995; 84():237-44. PubMed ID: 7796960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
    Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
    J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
    [No Abstract]   [Full Text] [Related]  

  • 4. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
    Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
    Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity and immunogenicity of oral cholera vaccine in Thai volunteers.
    Migasena S; Pitisuttitham P; Supanaranond W; Desakorn V; Prayurahong B; Suntharasamai P
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):423-8. PubMed ID: 3217824
    [No Abstract]   [Full Text] [Related]  

  • 9. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination].
    Sumarokov AA; Ivanov NR; Lelikov VL; Dzhaparidze MN; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1978; (12):87-92. PubMed ID: 371293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient Intestinal Colonization by a Live-Attenuated Oral Cholera Vaccine Induces Protective Immune Responses in Streptomycin-Treated Mice.
    Fakoya B; Sit B; Waldor MK
    J Bacteriol; 2020 Nov; 202(24):. PubMed ID: 32540930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cloning of the Vibrio cholerae recA gene and construction of a Vibrio cholerae recA mutant.
    Goldberg I; Mekalanos JJ
    J Bacteriol; 1986 Mar; 165(3):715-22. PubMed ID: 3005236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.
    Jertborn M; Svennerholm AM; Holmgren J
    J Infect Dis; 1988 Feb; 157(2):374-7. PubMed ID: 3335813
    [No Abstract]   [Full Text] [Related]  

  • 14. Kinetics of the vibriocidal antibody response to live oral cholera vaccines.
    Wasserman SS; Losonsky GA; Noriega F; Tacket CO; Castañeda E; Levine MM
    Vaccine; 1994 Aug; 12(11):1000-3. PubMed ID: 7975839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of a candidate live oral typhoid/cholera hybrid vaccine in humans.
    Forrest BD; LaBrooy JT; Attridge SR; Boehm G; Beyer L; Morona R; Shearman DJ; Rowley D
    J Infect Dis; 1989 Jan; 159(1):145-6. PubMed ID: 2909633
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene sequence of recA+ and construction of recA mutants of Vibrio cholerae.
    Stroeher UH; Lech AJ; Manning PA
    Mol Gen Genet; 1994 Aug; 244(3):295-302. PubMed ID: 8058040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits.
    Eko FO; Schukovskaya T; Lotzmanova EY; Firstova VV; Emalyanova NV; Klueva SN; Kravtzov AL; Livanova LF; Kutyrev VV; Igietseme JU; Lubitz W
    Vaccine; 2003 Sep; 21(25-26):3663-74. PubMed ID: 12922096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
    Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
    Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.
    Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB
    Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.